Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | P4HB | P07237 | 2/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484280 | 1.00 | LMNA (0.53) | LMNANPSR1SMN1; SMN2POLBPKM | |
| SCHEMBL3483861 | 0.90 | P4HB (0.60) | LMNANPSR1SMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL3483862 | 0.90 | P4HB (0.60) | LMNANPSR1SMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL3484275 | 0.89 | LMNA (0.55) | LMNANPSR1SMN1; SMN2POLBPKM | |
| SCHEMBL30384331 | 0.89 | LMNA (0.55) | LMNANPSR1SMN1; SMN2POLBPKM | |
| SCHEMBL3484270 | 0.89 | LMNA (0.55) | LMNANPSR1SMN1; SMN2POLBPKM | |
| SCHEMBL25191789 | 0.88 | HDAC1 (0.53) | LMNANPSR1SMN1; SMN2PKMHDAC1 | |
| SCHEMBL3484285 | 0.87 | HDAC1 (0.55) | LMNASMN1; SMN2HDAC1HDAC8P4HB | |
| SCHEMBL3484287 | 0.87 | HDAC1 (0.55) | LMNASMN1; SMN2HDAC1HDAC8P4HB | |
| SCHEMBL3484498 | 0.86 | F3 (0.56) | LMNANPSR1SMN1; SMN2HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | claimed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | claimed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | claimed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | claimed |
| EP-2099440-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | Seoul National University Industry Foundation (KR) | 2009-09-16 | — | — | EP | claimed |
| WO-2008069608-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-12 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | disclosed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | disclosed |
| US-8445722-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2013-05-21 | — | — | US | disclosed |
| EP-2099440-B1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 | SEOUL NAT UNIV IND FOUNDATION (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120282619-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY | 2012-11-08 | — | — | US | disclosed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-2099440-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | Seoul National University Industry Foundation (KR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008069608-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | LMNA 1180/4885NPSR1 4347/4885SMN1; SMN2 3415/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | LMNA 1817/4885NPSR1 4282/4885SMN1; SMN2 4161/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | LMNA 1817/4885NPSR1 4282/4885SMN1; SMN2 4161/4885 |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | TM9SF4, TM9SF2, TM9SF3 | LMNA 1874/4885NPSR1 4804/4885SMN1; SMN2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.